Abstract: Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

Abstract: Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

Abstract: The present invention relates to novel methods of treating Hepatitis B Virus by administering a KDM5 inhibitor.

Abstract: The present invention relates to novel methods of treating Hepatitis B Virus by administering a KDM5 inhibitor.

Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

Abstract: This invention concerns certain 5-(substituted amino) isothiazoles, compounds of Formula I, and salts thereof, where Q is CN, NHCONRaRb, or CONRaRb, where Ra and Rb are defined herein; and R1 is cyclohexyl, adamantan-1-yl, indan-1-yl, phenyl, benzyl, pyridyl, pyridylmethyl, or pyrimidyl, where all aromatic R1 groups are optionally substituted, provided that when R1 is phenyl, then R1 bears at least one non-alkyl substituent, and further provided that R1 is not 4-chloro-3-trichloromethyl-phenyl; The invention also concerns the tautomeric 5-(substituted amino)-isothiazol-3(2H)-ones, and the use of such compounds to treat Hepatitis C infection. It also concerns thiocarbamoyl acetamides, which are synthetic precursors to the isothiazoles.

Abstract: A polymerase inhibitor has first moiety coupled to a second moiety via an optional linker in which the first moiety binds to an initiation nucleotide binding site of a polymerase and forms at least two hydrogen bonds with an RNA template strand that is associated with the polymerase, and in which the second moiety comprised a compound that binds to a site proximal to the nucleotide binding site of the polymerase and thereby increases the affinity of the polymerase inhibitor to the polymerase.

Abstract: A polymerase inhibitor has first moiety coupled to a second moiety via an optional linker in which the first moiety binds to an initiation nucleotide binding site of a polymerase and forms at least two hydrogen bonds with an RNA template strand that is associated with the polymerase, and in which the second moiety comprised a compound that binds to a site proximal to the nucleotide binding site of the polymerase and thereby increases the affinity of the polymerase inhibitor to the polymerase.